Trials / Recruiting
RecruitingNCT07499817
Effect of Pentoxyfilline on Endometrial Thickness and Frozen Embryo Transfer Outcomes
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Beni-Suef University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 43 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this work was to investigate the effect of different vasodilators as pentoxifylline in women with unexplained infertility using IVF
Detailed description
A prospective randomized clinical study was carried out on 100 women, aged \<18 to 43 years old, has good quality day five frozen embryos. The study was done after approval from the Ethical Committee Beni Suef University Hospitals, Beni Suef, Egypt. An informed written consent was obtained from the patients. Randomization and blindness: An online randomization program (http://www.randomizer.org ) was used to generate a random list and each patient's code was kept in an opaque sealed envelope. Patients were randomly allocated with 1:1 allocation ratio into two equal groups in a parallel manner: Group 1 (control): received estradiol valerate 2 mg. in form of (Cycloprogynova® Bayer Shering Pharma) whitepills starting dose is one pill T.I.D may be increased to two pills T.I.D according to endometrial5 thickness in day 9 measured by vaginal ultrasound. Group 2: received pentoxifylline 400 mg. Once daily in form of (Trental ® Sanofi co.) daily in addition to the above treatment protocol from the first day of the cycle until the day of starting progesterone. All patients were subjected to complete history taking, general examination, laboratory investigations \[Anti-müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E₂), prolactin (PRL) and thyroid-stimulating hormone (TSH)\] and radiological investigations \[Ultrasonography\]. The endometrial thickness was estimated by transvaginal ultrasonography.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pentoxifylline 400 mg | Once daily in form of (Trental ® Sanofi co.) daily in addition to the above treatment protocol from the first day of the cycle until the day of starting progesterone. |
| OTHER | (control) | estradiol valerate 2 mg. in form of (Cycloprogynova® Bayer Shering Pharma) whitepills starting dose is one pill T.I.D |
Timeline
- Start date
- 2023-10-01
- Primary completion
- 2026-04-01
- Completion
- 2026-04-30
- First posted
- 2026-03-30
- Last updated
- 2026-03-30
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT07499817. Inclusion in this directory is not an endorsement.